SCHEMBL4091737

SCHEMBL4091737

CCCCOc1ccc(NC(=O)N(Cc2ccc(C(C)(C)C)cc2)Cc2ccc(C(=O)NCCC(=O)O)s2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 14/20 0.50
GLP1R P43220 2/20 0.50
GIPR P48546 2/20 0.50
ADCY6 O43306 4/20 0.42
ADCY3 O60266 4/20 0.42
ADCY9 O60503 4/20 0.42
ADCY5 O95622 4/20 0.42
ADCY8 P40145 4/20 0.42
ADCY7 P51828 4/20 0.42
ADCY2 Q08462 4/20 0.42
ADCY1 Q08828 4/20 0.42
ADCY4 Q8NFM4 4/20 0.42
S1PR1 P21453 2/20 0.41
S1PR3 Q99500 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ACKR3 P25106 1/20 0.40
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4086646 0.84 GCGR (0.46) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2663142 0.83 GCGR (0.51) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2663017 0.81 GCGR (0.45) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2663131 0.81 GCGR (0.60) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL4091740 0.77 GCGR (0.46) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2663133 0.76 GCGR (0.55) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2662994 0.76 GCGR (0.42) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL12056563 0.73 GCGR (0.47) GCGRGIPRADCY6ADCY3ADCY9
SCHEMBL7132610 0.72 GCGR (0.71) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL1811686 0.72 SMN1; SMN2 (0.48) GCGRGLP1RGIPRNR1H4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885GIPR 4/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885GIPR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.